Measuring eosinophiluria, urinary eosinophil cationic protein and urinary interleukin-5 in patients with Lupus Nephritis by Tereza Neuma Souza Brito et al.
ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
Brito et al. Allergy, Asthma & Clinical Immunology 2014, 10:61
http://www.aacijournal.com/content/10/1/61RESEARCH Open AccessMeasuring eosinophiluria, urinary eosinophil
cationic protein and urinary interleukin-5 in
patients with Lupus Nephritis
Tereza Neuma Souza Brito1, Maria José Vilar2, José Bruno Almeida3, Ana Luiza Souza Brito Faria4,
Sarah Dantas Viana Medeiros5, Maria Carmo Cardoso Medeiros6, Edna Marques Araújo Silva1,
Vanessa Marques Araújo Silva5, Luanda Bárbara F Canário Souza7, Luisa Karla P Arruda8, Tatiana Xavier Costa5,
Geraldo Barroso Cavalcanti Junior1, Antonio G Oliveira9 and Valéria Soraya Farias Sales1*Abstract
Background: Urine is increasingly becoming an attractive biological fluid in clinical practice due to being an easily
obtained, non-invasive sampling method, containing proteins and peptides. The aim of this study was to investigate
eosinophiluria, urinary eosinophil cationic protein (uECP) and urinary IL-5 (uIL-5) in patients with Lupus Nephritis.
Methods: Seventy-four patients with SLE—20 with clinical and laboratory evidence of lupus nephritis (LN group)
and 54 without evidence of renal involvement (non-LN group)—were analyzed regarding eosinophiluria, uECP and
uIL-5. Eosinophiluria was observed by Hansel's stain, ECP by fluoroenzymeimmunoassay and uIL-5 by quantitative
sandwich enzyme immunoassay. Both uECP and urinary IL-5 (uIL-5) were corrected by urinary creatinine. Eosinophiluria
and uECP were compared with glomerular erythrocyturia, protein/creatinine ratio (Pr/Cr ratio), serum creatinine,
estimated glomerular filtration rate (eGFR), anti-double-stranded DNA (anti-dsDNA), serum levels of complement
(C3 and C4), uIL-5/Cr ratio, and SLE disease activity index.
Results: Patients of the LN group had higher eosinophiluria, uECP, uECP/Cr ratio levels, and uIL-5 than patients of
the non-LN group (p<0.001 for all). These variables showed a statistically significant correlation with glomerular
erythrocyturia, casts, Pr/Cr ratio, serum creatinine, eGFR, anti-dsDNA, uIL-5/Cr, and SLE disease activity index (all
p<0.05).
Conclusion: These results provide evidence of increased urinary eosinophils, ECP and IL-5 in patients with SLE and
LN; uECP/Cr ratio showed better correlation with markers of renal function and SLE disease activity.
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Systemic lupus erythematosus (SLE) is a multifactorial
autoimmune disorder characterized by autoantibody
production, immune complex formation, and immuno-
logically mediated tissue injury [1]. Lupus nephritis (LN)
is one of the most serious manifestations of SLE, which
affects 25–60% of patients, and one of the leading causes
of morbidity and mortality of this disease [2-6].* Correspondence: vsales10@gmail.com
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unless otherwise stated.Although the precise pathogenesis of LN has not been
fully elucidated, it is mostly attributable to the glomeru-
lar deposition of immune complexes and imbalance of
the cytokine homeostasis, [7] which leads to a cascade of
inflammatory events with recruitment of mononuclear
cells, such as T cells, macrophages, and dendritic cells
[8]. There is considerable evidence of the role of Th1,
Th17, and regulatory T (Treg) cells in SLE, and studies
have suggested a possible contribution of Th2 cells [9].
Among the cells that can secrete cytokines capable of
promoting T-cell proliferation, activation of Th1, or Th2
polarization is the eosinophil. This is a granulocyte that
has been implicated in the modulation of both innated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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verse stimuli, eosinophils are recruited from the circula-
tion to inflammatory foci where they modulate immune
responses through an array of mechanisms, such as
secretion of cationic proteins and expression of recep-
tors for cytokines, immunoglobulins, complement, and
mRNA for a number of Toll-like receptors. They can
initiate antigen-specific immune responses by acting as
antigen-presenting cells [10-14].
Once attracted to the site of inflammation, eosinophils
becomes activated and four highly cytotoxic cationic
protein preformed granules are secreted. They are the
eosinophil cationic protein (ECP), eosinophil peroxidase
(EPO), eosinophil derived neurotoxin (EDN)/former eo-
sinophil protein X (EPX) and major basic protein (MBP),
in addition to chemokines, cytokines, and growth factors.
ECP is the best known of these, has been assessed and
used as a marker in asthma and other inflammatory dis-
eases, and has been scrutinized in a number of functional
studies. Regarding cytokines, IL-5 is the most specific to
the eosinophil lineage and is responsible for selective
differentiation, regulating growth, activation, and survival
of eosinophils [10,15,16].
Based on the findings of eosinophils in the urine of
SLE patients and on the role of eosinophils in various
inflammatory diseases, this study was aimed to evaluate
eosinophiluria, uECP and uIL-5 levels of SLE patients as




Patients with SLE diagnosis according to the American
College of Rheumatology (ACR) [1] criteria, age ≥18
years, were selected in the Rheumatology Unit Hospital
Onofre Lopes (HUOL), Federal University of Rio Grande
do Norte (UFRN), Natal, Brazil, a region with high
incidence of this disease [17]. Informed consent was
obtained from the patients after approval by the local
ethics committee, number 044/2006. The study was con-
ducted according to the ethical guidelines of our institu-
tion (UFRN) and the Declaration of Helsinki. Disease
activity was assessed by the Mexican version of the
SLE Disease Activity Index (MEX-SLEDAI) [18]. Patients
with immunodeficiency, history of allergy, manifestations
of vasculitis, other autoimmune diseases, helminthiasis,
prostate cancer, renal cancer, bladder infections, nephro-
lithiasis, and urinary tract infections were excluded from
the study.
The patients were divided into two groups. The first
group (the LN group) consisted of patients with active
renal manifestations of SLE and clinical and laboratory
evidence suggestive of lupus glomerulonephritis. The
presence of renal disease activity was defined by MEX-SLEDAI score ≥6 and by the presence of all of the follow-
ing in the urine test: haematuria ≥1+, proteinuria ≥2+, ac-
tive urinary sediment with erythrocyturia defined as ≥5
cells/high power field (HPF or 40× magnification), casts
(erythrocyte and/or granular, fatty, waxy, and renal tubular
epithelial cells), and glomerular dysmorphic erythrocytes.
In addition, the patients of the LN group also had to
present serum creatinina ≥1mg/dL, eGFR ≤60 mL/min,
proteinuria 24-hours ≥3g/L, protein in the first morning
urine (spot urine) corrected by creatinine (Pr/Cr ratio) ≥3,
positive titers of anti-dsDNA (≥1:40), and decreased con-
centrations of serum C3 and C4. The second group (the
non-LN group) consisted of patients with MEX-SLEDAI
score <6 and without laboratory evidence of renal
involvement.
All patients were medicated with prednisone at a max-
imum dose of 10 mg/day and antimalarial drugs. In
order to prevent further renal damage, patients in the
LN group had prednisone increased to ≥1 mg/kg/day,
up to a maximum of one week before inclusion into the
study. Once data had been collected, cyclophosphamide
0.5-1.0 g/cm2 was added to the prednisone regime, as
well as antimalarial drugs, calcium channel blockers,
angiotensin-converting enzyme (ACE) inhibitors, proton
pump inhibitors, and diuretics.
Laboratory measurement
The laboratory evaluation included stool analysis, 10 mL
of venous blood and, the first morning urine. The
venous blood was allowed to clot for 60 min at 24°C,
followed by centrifugation (10 min, 24°C, 1600 G). The
resulting serum samples were tested for anti-dsDNA,
creatinine, eGFR, C3, and C4.
Standard urinalysis for glomerular dysmorphic eryth-
rocytes, eosinophiluria, protein, and creatinine was per-
formed in the first morning urine, midstream. The
supernatant (after centrifugation 5 min, 24°C, 400 G)
was stored at −80°C until analysis of uECP and uIL-5.
Next, this sample was measured and centrifuged (5 min,
24°C, 400 G) for determination of proteinuria and glom-
erular filtration rate (creatinine clearance). Urinalysis
was performed by experienced personnel following the
good quality control procedures.
In this study, proteinuria was defined as Pr/Cr ratio,
due to a strong correlation between the results found by
two methods and in accordance with the recommenda-
tion of the Renal Disease Subcommittee of the American
College of Rheumatology Ad Hoc Committee on Sys-
temic Lupus Erythematosus Response Criteria [19].
Eosinophiluria assessed by Hansel's stain was con-
ducted after concentrating 50 μL of urine sediment in a
cytospin cytocentrifuge. The eosinophils were counted
per 10 high-power fields (HPF) and the finding of even a
single one was considered positive eosinophiluria [20].
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therefore evaluated by three experienced analysts.
The uECP measurements were performed by the
Pharmacia CAP System® ECP FEIA (fluoroenzymeimmu-
noassay) (Pharmacia, Uppsala, Sweden), with a coefficient
of variation of 2.5%, according to the manufacturer’s in-
structions. The test is designed as a sandwich immuno-
assay. Inter- and intra-assay coefficients of variation were
less than 8% and the detection limit was 0.5 μg/L. The
uECP was determined following the same instructions
used for serum ECP, and uECP levels were corrected to
urine creatinine (uECP/Cr ratio) with results expressed as
micrograms per milligram of creatinine (μg/mgCr).
The concentrations of uIL-5 were determined by
quantitative sandwich enzyme immunoassay (Quantikine®
Minneapolis, United States of America), according to the
manufacturer’s instructions. This immunoassay is a solid
phase ELISA designed to measure IL-5 levels in cell cul-
ture supernates, serum, plasma, and urine; the detection
limit was <3,0 pg/mL. Concentrations of uIL-5 levels were
corrected to urine creatinine (uIL-5/Cr ratio) and results
were expressed as picrograms per milligram of creatinine
(pg/mgCr).
Statistical analyses
Statistical analyses were performed with SPSS v.17 for




Disease duration of SLE (months) mean±SD
Mex-SLEDAI mean±SD
Dipstick positive hematuria - (1+ to 4+), % (n)
Dysmorphic erythrocyte, % (n)
Erythrocyte, granular, fatty and waxy casts, % (n)
Oval fat bodies, % (n)
Erythrocytes sedimentation rate/HPF mean±SD
Dipstick positive proteinuria (1+ to 4+), % (n)
Pr/Cr ratio (mg/mg) mean±SD
24-h Proteinuria (g/L) mean±SD
Serum creatinine (μmol/L) mean±SD
eGFR (mL/min) mean±SD
Creatinine clearance (mL/min/1.73 m2) mean±SD
Serum C3 (mg/L) mean±SD
Serum C4 (mg/L) mean±SD
Anti-dsDNA title mean±SD
HPF, high power field or 400X.
*p-value <0.05.were tested for normal distribution using the Shapiro-
Wilk and Kolmogorov-Smirnov statistical tests. Results
are presented as mean±standard deviation (SD), median,
interquartile range (IQR), and minimum (min) and max-
imum (max) values. uECP correlation with disease activity
and renal function tests was assessed using Pearson and
Spearman's rank correlation coefficient.
Categorical variables were compared between groups
with the chi-square test and continuous variables were
compared with the Student's t-test and the Mann-
Whitney’s U-test. Two-tailed p-values less than 0.05 were
regarded as statistically significant. Assuming a signifi-
cance level (α) of 0.05 and a power (1 – β) of 80%, the
sample size used was able to detect statistical significance
for differences between groups of 1.5 cells in eosinophiluria,
3.9 μg/L in uECP, and 6.5 μg/mgCr in uECP/Cr ratio.
Results
Baseline characteristics of patients
A total of 74 patients with SLE—20 patients (16 women
and 4 men) with active SLE and evidence of LN (MEX-
SLEDAI score 5.0-22.0) and 54 patients (all women)
with inactive disease and without LN (MEX-SLEDAI
score <1)—were evaluated for eosinophiluria, uECP, and
uIL-5. The demographic characteristics and laboratory
parameters of the two groups are presented in Table 1.
The mean age was 29.5±8.5 years and the mean diseaseLE patients with and without lupus nephritis (LN)






100.0 (20)* 0.0 (0)
70.0 (14)* 1.8 (1)
70.0 (14)* 7.4 (4)
80.0 (16)* 1.8 (1)
33.8±16.3* 1.9±1.7
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There were no significant differences in ethnicity be-
tween the two groups of patients. Only three patients of
the LN group also received one intravenous pulse of
cyclophosphamide (0.5 g/m2 body surface area) in the
same period.Laboratory findings
Eosinophiluria (as shown in Figure 1) was observed in
45% (n=9) of the patients in the LN group and 5.6%
(n=3) in the non-LN group. The mean urinary eosino-
phil count /HPF was significantly higher in patients in
the LN group than that in patients in the non-LN group
(p<0.001). The concentrations of uECP, uECP/Cr ratio,
uIL-5, and uIL-5/Cr ratio were higher in the LN group
than in the non-LN group (p <0.05), (Table 2, Figure 2).
In addition, a statistically significant correlation was
observed between study variables and markers of active
renal disease (Table 3), such as haematuria, glomerular
dysmorphic erythrocytes, casts, Pr/Cr ratio, serum cre-
atinine, eGFR, anti-dsDNA, serum C3, serum C4, and
SLE disease activity index (all p<0.05). The strongest
associations were observed between uECP/Cr ratio and
haematuria (rs=0.76), Pr/Cr ratio (rs=0.75), serum cre-
atinine (rs=0.70) and MEX-SLEDAI (rs=0.72), p<0.001.
Urinary IL-5 and uIL-5/Cr ratio showed a statistically
significant correlation with eosinophiluria, uECP and
uECP/Cr ratio (p<0.05). The uIL-5/Cr also showed a
statistically significant correlation with MEX-SLEDAI
(rs=0.41), p<0.01.Discussion
This study is the first to investigate eosinophiluria, uECP
and uIL-5 as a possible marker to evaluate renal inflam-
matory activity of SLE patients. We selected patients
with clinical and laboratory features strongly suggestive
of LN, and control patients without evidence of LN. This
study revealed a statistically significant increase inFigure 1 Eosinophiluria by Hansel’s stain (400X) (arrow).eosinophiluria, uECP and uIL-5 in patients with LN
compared with patients without LN.
Lupus nephritis requires long-term monitoring over
several years, as flares as well as progressive deterior-
ation of renal function may occur. Evaluation for LN
includes dipstick and urine sediment analysis, urinary
protein and creatinine excretion, determination of serum
creatinine and assessment of serological markers such as
anti-dsDNA antibody titres and C3 and C4 levels. The
combination of these markers is a powerful measure for
the detection of active renal manifestations of SLE.
However renal biopsy remains the gold standard to as-
sess disease severity, but multiple biopsies to gauge
treatment efficacy are not feasible due to their invasive
nature with risks of bleeding and infection, thereby pre-
senting a less satisfactory method for monitoring renal
involvement in SLE [21-23].
Urinary biomarkers may also reflect to some extent
the degree of tubular dysfunction, rather than purely
reflecting underlying glomerular pathology [24]. A bio-
marker that could forecast lupus nephritis flares well
before thresholds of proteinuria, renal function and
urine sediment that signal clinical flare are reached
would be a valuable tool [25]. Thus, novel biomarkers
that are able to discriminate lupus renal activity and its
severity, predict renal flares, and monitor treatment re-
sponse and disease progress are clearly necessary [26,27].
The clinical and laboratory differences presented be-
tween the two groups of patients selected for this study
were consistent with literature data. Marks et al. [28]
found that LN patients had higher urine albumin/creatin-
ine ratios compared to non-nephritis patients. Rubinstein
et al. [29] found proteinuria (Pr/Cr ratio) greater than 2.0,
decreased creatinine clearance, and SLE disease activity
index (SLEDAI) ≥4 in SLE patients with biopsy-proven
nephritis. A study by Guo et al. [30] found, in patients
with LN class IV, values of 24-h proteinuria ≥3 g/day,
increased serum creatinine, and a mean SLEDAI ≥9 in all
patients, suggesting that most SLE patients with renal
diseases were in the active stage.
Urine as a biological sample has the advantage that it
is easily obtainable by non-invasive means and thus al-
lows investigators to avoid many regulatory hurdles [31].
This study showed that eosinophiluria, uECP, uECP/Cr
and uIL-5 levels were higher in the LN group than in
the non-LN group. Eosinophiluria has a higher fre-
quency in the LN group and showed a consistent and
statistically significant correlation with a number of eval-
uated parameters of renal inflammation and dysfunction.
Eosinophiluria has been suggested to be useful in estab-
lishing the diagnosis of acute interstitial nephritis. Some
diseases of the urinary tract are accompanied by pyuria
and eosinophilic tissue infiltration but have not been
tested for urinary eosinophils. These diseases include
Table 2 Laboratory values for 74 SLE subjects with and without renal disease
LN group (n=20) non-LN group (n=54) p-value
Eosinophiluria, % (n) 45.0 (9.0)* 5.6 (3.0) <0.001
Urinary eosinophil count /HPF mean±SD 1.1±1.65* 0.15±0.59 <0.001
Urinary ECP (μg/L), mean±SD 4.58±3.18* 2.12±0.36 <0.001
Urinary ECP/Cr ratio (μg/mgCr) mean±SD 96.56±53.70* 34.55±12.66 <0.001
Urinary IL-5 (pg/mL) mean±SD 144.52±95.59* 61.68±73.51 <0.001
Urinary IL-5/Cr ratio (pg/mgCr) mean±SD 299.72±208.63* 106.21±134.898 <0.001
HPF, high power field or 400X; ECP, eosinophil cationic protein; uECP/Cr ratio, eosinophil cationic protein-creatinine ratio; uIL-5, urinary Interleukin-5.
*p-value <0.05.
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infiltration surrounding bladder cancer, eosinophilic glom-
erulonephritis, and atheroembolic renal disease [32-34].
As renal biopsies were not performed in our study, we
are not able to unequivocally state that the positive eosi-
nophiluria was entirely of renal origin. As a matter of
fact, one might question whether that eosinophiluria
could be due to active disease rather than to lupus neph-
ritis. However, to classify the two study groups based on
renal biopsy would require that a large number of pa-
tients with no clinical or laboratorial evidence of renal
lesion had to be needlessly submitted to the risk of renal
biopsy. Therefore, in order to avoid exposing study sub-
jets to that risk at the same time to minimize the
chances that patients without lupus nephritis could be
included in the LN group, we imposed the constraint
that patients were classified in the LN group only if they
had active SLE, in addition to clinical and laboratorialFigure 2 Urinary eosinophil count/HPF, ECP (μg/L), IL-5 (pg/mL), ECP/
lupus nephritis (LN).manifestations of renal disease. Conversely, the chances
of including patient with lupus nephritis in the control
group were minimized by excluding subjects with mani-
festations of renal disease or active SLE. Although this
design caused nephritis to be statistically confounded
with active disease, we are convinced that eosinophiluria
is not related to active SLE, a conviction that is further
reinforced by the observation that there was no statisti-
cally significant difference (p=0.52) in the absolute count
of eosinophils in the peripheral blood between the LN
group (142.7±32.5/ml) and controls (160.3±20.4).
The literature does not report the participation of
eosinophils in the inflammatory process of LN. However,
studies probing the immunobiology of eosinophils have
uncovered an evolving story in which eosinophils partici-
pate in innate immune processes as more than terminal
effector cells. An appreciation of chemokines, cytokines
and growth factors derived from their granules, both inCr (μg/mg) and IL-5/Cr (pg/mg) in SLE patients with and without
Table 3 Rank correlation between study variables and
laboratory parameters that evaluate the involvement of









Casts 0.44 0.45 0.63*
Pr/Cr ratio 0.46 0.55* 0.75*
Serum creatinine 0.59* 0.57* 0.70*
eGFR −0.54* −0,47 −0.61*
Anti-dsDNA 0.26 0.27 0.58*
Serum C3 −0.21 −0.16 −0.30
Serum C4 −0.28 −0.44 −0.31
Urinary IL-5 0.31 0.32 0.27
Urinary IL-5/Cr (pg/mgCr) 0.36 0.28 0.50*
Mex-SLEDAI 0.41 0.44 0.72*
ECP, eosinophil cationic protein; Pr/Cr ratio, protein-creatinine ratio; C3,
complement 3; C4, complement 4; Mex-SLEDAI, Mexican version of the SLE
Disease Activity Index. *p-value <0.05.
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recently discovered functions of that cell, including
regulation of the immune microenvironment, inflamma-
tory response, homeostasis and tissue remodeling. The
demonstration that eosinophils can be antigen-presenting
cells in mice and humans, establish eosinophils as
cells that participate in innate and adaptive immunity
[10,12,35]. Thus, based on these data we can suggest
that eosinophils may play a role in kidney inflamma-
tion in LN.
Studies have shown that during inflammation whole
eosinophil granules are released from disrupted cells and
those internal proteins are subsequently released differ-
entially through the process of piecemeal degranulation.
Among the components of these granules, ECP is RNAse
A superfamily, protein rich in arginine residues, which
gives a high concentration of positive charges, promoting
a strong attraction for molecules negatively charged exist-
ing in cell membranes [15,16,36]. This property may ex-
plain its cytotoxic power in the cell membranes causing
the formation of pores or channels on the surface of the
membrane, disrupting its lipid structure and possibly fa-
cilitating the entry of other cytotoxic molecules. Sensitive
assays have been developed for its measurement in bio-
logical fluids which have contributed to the understanding
of the role of the eosinophils in disease [10,15].
This study demonstrated increased uECP in patients
of the LN group compared to non-LN group patients
and a statistically significant correlation between the
concentration of uECP and haematuria, glomerular dys-
morphic erythrocytes, casts, Pr/Cr ratio, serum creatinine,eGFR, uIL-5, and MEX-SLEDAI. Interestingly, after cor-
rection of uECP by creatinine (ECP/Cr ratio), an increase
was noted in the correlation with haematuria, Pr/Cr ratio,
serum creatinine and MEX-SLEDAI.
Inflammatory diseases tend to share common path-
ways and thus many a potential biomarker will not be
specific for a particular disease. Few biomarkers for SLE
have been validated and employed for making clinical
decisions given the complex etiopathogenesis, heteroge-
neous clinical manifestations, and varying rates of dis-
ease progression among individual SLE patients [3,27].
In the present study, uIL-5 had higher concentration
in the LN group and after being corrected by creatinine
(uIL-5/Cr ratio) showed better correlation with the uECP/
Cr ratio and with MEX-SLEDAI. No article has yet been
published in the literature about the uIL-5/Cr ratio in
SLE. The increased levels of uIL-5 can justify the appear-
ance of eosinophils and ECP in urine of the SLE patients
studied because the cytokine IL-5, which is a key Th2
cytokine in eosinophil biology, is involved in eosinophil
differentiation, maturation, migration and activation of
these cells [37].
This is the first study showing that eosinophiluria,
urinary ECP and IL-5 may be useful as biomarkers of
renal inflammation in SLE patients. The data are en-
couraging and provide a basis for future research. Our
findings not only suggest that uECP/Cr ratio may be a
urinary biomarker of renal inflammatory activity in SLE
patients but also shows the need to investigate the role
of eosinophils in the inflammatory process of nephritis
in patients with systemic lupus erythematosus.
In conclusion, we showed increased urinary eosino-
phils, uECP/Cr ratio and uIL-5 levels in patients with
history of lupus nephritis. Urinary ECP/Cr ratio might
serve as a novel marker of renal inflammation in SLE.
Evidently, more research is needed to verify the behavior
of these biomarkers in both groups.
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